Pharmaceutical giant Eli Lilly has unveiled plans to construct a major production facility for injectable medicines and delivery devices in Fogelsville, located within Pennsylvania’s Lehigh Valley. The project involves a projected investment of $3.5 billion and will primarily focus on manufacturing next-generation metabolic therapies, including the investigational drug retatrutide.
The site represents the company’s fourth U.S.-based manufacturing announcement since early 2025, forming a key part of a broader $50 billion capital expenditure strategy to bolster domestic production capacity. The Lehigh Valley location was selected from over 300 candidates due to its robust infrastructure, transport links, and proximity to specialized engineering and scientific talent from local academic institutions.
Construction is scheduled to commence in 2026, with full operations expected to begin by 2031. The initiative is forecasted to generate approximately 2,000 construction jobs and 850 permanent professional roles. Technically, the facility aims to utilize artificial intelligence and advanced data analytics to enhance manufacturing efficiency and secure the supply chain for essential chronic care treatments.
Source: https://www.pharmexec.com/view/eli-lilly-3-billion-manufacturing-facility-pennsylvania